HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pulse itraconazole 400 mg daily in the treatment of chromoblastomycosis.

Abstract
Pulse itraconazole is effective in the treatment of chromoblastomycosis caused by Fonsecaea pedrosoi. Six patients, mean 62.3 years (range 45-79), mean duration 103 months (range 4 months to 30 years), were included in this study. F. pedrosoi was the only isolated organism. Four patients (66.7%) were cured by 12 months. Two patients (33.3%) failed to respond fully to treatment; however, one patient whose culture remained positive showed > 50% improvement at the end of study. Data showed that duration and severity were not predictive of treatment response. No side-effects were noted. Treatment should be continued until absence of organisms is proven by histology and tissue culture. Pulse regimen is more economical with better compliance than the conventional continuous 200-400 mg daily regimen, although optimum treatment duration depends on individual cases.
AuthorsR Ungpakorn, S Reangchainam
JournalClinical and experimental dermatology (Clin Exp Dermatol) Vol. 31 Issue 2 Pg. 245-7 (Mar 2006) ISSN: 0307-6938 [Print] England
PMID16487103 (Publication Type: Journal Article)
Chemical References
  • Antifungal Agents
  • Itraconazole
Topics
  • Aged
  • Antifungal Agents (administration & dosage)
  • Chromoblastomycosis (drug therapy, microbiology)
  • Female
  • Humans
  • Itraconazole (administration & dosage)
  • Male
  • Middle Aged
  • Mitosporic Fungi
  • Prospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: